No connection

Search Results

APLM vs INCR

APLM
Apollomics, Inc.
BEARISH
Price
$19.90
Market Cap
$42.7M
Sector
Healthcare
AI Confidence
85%
INCR
InterCure Ltd.
BEARISH
Price
$0.76
Market Cap
$41.7M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
APLM
--
INCR
--
Forward P/E
APLM
-30.62
INCR
-0.52
P/B Ratio
APLM
-4.99
INCR
0.1
P/S Ratio
APLM
6.15
INCR
--
EV/EBITDA
APLM
-0.78
INCR
--

Profitability

Gross Margin
APLM
100.0%
INCR
16.71%
Operating Margin
APLM
-124.8%
INCR
0.0%
Profit Margin
APLM
0.0%
INCR
-29.18%
ROE
APLM
-380.13%
INCR
-16.68%
ROA
APLM
-72.29%
INCR
-7.74%

Growth

Revenue Growth
APLM
380.8%
INCR
3.4%
Earnings Growth
APLM
--
INCR
--

Financial Health

Debt/Equity
APLM
--
INCR
0.41
Current Ratio
APLM
0.97
INCR
1.85
Quick Ratio
APLM
0.91
INCR
1.08

Dividends

Dividend Yield
APLM
--
INCR
--
Payout Ratio
APLM
0.0%
INCR
0.0%

AI Verdict

APLM BEARISH

APLM's Piotroski F-Score of 3/9 indicates weak financial health, with significant red flags in profitability, cash flow, and leverage. The company exhibits extreme negative profitability metrics, including a -124.8% operating margin and -380.13% ROE, despite a 380.8% YoY revenue growth. With no Altman Z-Score available and a current ratio of 0.97, liquidity concerns persist. The stock trades at a high Price/Sales of 6.15 and a negative forward P/E of -30.62, suggesting valuation is driven by speculative growth expectations rather than fundamentals. The 52-week price range of $3.66 to $42.12 reflects extreme volatility, and the 5-year return of -98.0% underscores long-term underperformance.

Strengths
380.8% YoY revenue growth indicates strong top-line expansion
100.0% gross margin suggests efficient cost structure on sales
Recent 6-month return of +191.4% shows strong short-term momentum
Risks
Piotroski F-Score of 3/9 signals severe financial distress and weak operational health
Negative ROE (-380.13%) and ROA (-72.29%) indicate deep losses relative to equity and assets
Operating margin of -124.8% reflects unsustainable cost structure or one-time expenses
INCR BEARISH

InterCure Ltd. exhibits severe financial distress as evidenced by a weak Piotroski F-Score of 2/9, indicating poor operational efficiency and financial health. Despite a very low Price-to-Book ratio of 0.10, the company is trapped in a catastrophic long-term price decline, losing over 91% of its value over five years. Negative profit margins and crashing EPS growth suggest that the low valuation is a value trap rather than a bargain. The lack of analyst coverage and a 0/100 technical trend further reinforce a bearish outlook.

Strengths
Low Debt-to-Equity ratio (0.41) suggests manageable leverage
Current Ratio of 1.85 indicates adequate short-term liquidity
Positive Gross Margin (16.71%) shows core product viability
Risks
Severe operational weakness indicated by Piotroski F-Score of 2/9
Negative profit margins (-29.17%) and negative ROE (-16.68%)
Catastrophic price performance (-91.7% over 5 years)

Compare Another Pair

APLM vs INCR: Head-to-Head Comparison

This page compares Apollomics, Inc. (APLM) and InterCure Ltd. (INCR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile